In phase 1b JAVELIN trial, it was tried to evaluate avelumab anti-tumor activity according to two different cut-off values for defining PD-L1 positivity on tumor cells (≥1% and ≥5%): a similar benefit for both the threshold values in ORR, PFS and OS was observed, without better results by increasing the threshold value (16). Here, CD274 is linked to neoplasm.